193 related articles for article (PubMed ID: 1495553)
1. Frustrated by regulatory delays at FDA, biotech companies warm to user fees.
Gershon D
Nature; 1992 Aug; 358(6388):616. PubMed ID: 1495553
[No Abstract] [Full Text] [Related]
2. FDA user fee and Modernisation Act.
Donawa M
Med Device Technol; 2002 Dec; 13(10):27-9. PubMed ID: 12575526
[TBL] [Abstract][Full Text] [Related]
3. User fees to hasten FDA review.
Gershon D
Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
[No Abstract] [Full Text] [Related]
4. Biotech bonanza.
Stipp D
Fortune; 1999 Nov; 140(9):333-4. PubMed ID: 10623111
[No Abstract] [Full Text] [Related]
5. Spreading biotech dollars around Washington.
Senior M
Nat Biotechnol; 2013 Aug; 31(8):673-5. PubMed ID: 23929333
[No Abstract] [Full Text] [Related]
6. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
Reed SD; Califf RM; Schulman KA
Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
[TBL] [Abstract][Full Text] [Related]
7. Biotech jostles with pharma for slice of HIV market.
Katsnelson A
Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
[No Abstract] [Full Text] [Related]
8. FDA joins market.
Gershon D
Nature; 1993 Jul; 364(6433):93. PubMed ID: 8321293
[No Abstract] [Full Text] [Related]
9. New drug law to speed scientific review.
Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
[TBL] [Abstract][Full Text] [Related]
10. User fees for faster drug reviews. Are they helping or hurting the public health?
Thompson L
FDA Consum; 2000; 34(5):25-9. PubMed ID: 11590789
[No Abstract] [Full Text] [Related]
11. FDA to collect fees from drug companies.
Minn Med; 1992 Nov; 75(11):46. PubMed ID: 1435650
[No Abstract] [Full Text] [Related]
12. FDA user fees approved.
Clin Pharm; 1993 Jan; 12(1):3. PubMed ID: 8428431
[No Abstract] [Full Text] [Related]
13. New law broadens FDA safety authority, renews user fees.
Fox JL
Nat Biotechnol; 2007 Nov; 25(11):1189-90. PubMed ID: 17989653
[No Abstract] [Full Text] [Related]
14. Biotech entrepreneurs swoon over proposed fundraising changes.
Venkataramanan M
Nat Med; 2012 Jan; 18(1):3. PubMed ID: 22227645
[No Abstract] [Full Text] [Related]
15. Biotech and pharma face more costly clinical trials.
Brower V
Nat Biotechnol; 1998 Aug; 16(8):714. PubMed ID: 9702762
[No Abstract] [Full Text] [Related]
16. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
Zelenay JL
Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
[No Abstract] [Full Text] [Related]
17. The further evolution of biotech.
Nagle T; Berg C; Nassr R; Pang K
Nat Rev Drug Discov; 2003 Jan; 2(1):75-9. PubMed ID: 12509762
[TBL] [Abstract][Full Text] [Related]
18. FDA user fees and innovation.
Somberg J
Am J Ther; 2008; 15(2):97. PubMed ID: 18356626
[No Abstract] [Full Text] [Related]
19. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
20. Spinning the wheel on ImClone.
Varchaver N
Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
[No Abstract] [Full Text] [Related]
[Next] [New Search]
